Fresenius SE & Co KGaA
F:FREA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
Fresenius SE & Co KGaA
F:FREA
|
DE |
|
M
|
Manulife Financial Corp
XBER:MLU
|
CA |
|
Opthea Ltd
F:UKJ
|
AU |
|
Banco Santander SA
MAD:SAN
|
ES |
|
Grenke AG
F:GLJ
|
DE |
|
E
|
Eli Lilly and Co
XHAM:LLY
|
US |
Fresenius SE & Co KGaA
Fresenius SE & Co KGaA is a healthcare company that makes medical products and runs hospitals. Its product side, Fresenius Kabi, sells things like IV fluids, injectable medicines, clinical nutrition products, infusion pumps, and other supplies used in hospitals and clinics. Its hospital side treats patients through large hospital networks in Germany and Spain, where it provides inpatient care, surgeries, and related medical services. The company makes money in two main ways. First, it sells healthcare products to hospitals, pharmacies, and other medical providers. Second, its hospital businesses are paid by insurers, public health systems, and patients for treatment and procedures. That mix gives Fresenius a role on both sides of the healthcare system: it supplies the tools doctors need and also delivers the care itself. What makes Fresenius different is that it sits close to the core of everyday healthcare rather than selling optional consumer products. Demand for its services and supplies is tied to surgery, chronic illness treatment, and routine hospital care, which makes the business easy to understand: when hospitals need dependable medical consumables and when patients need care, Fresenius is often part of the chain.
Fresenius SE & Co KGaA is a healthcare company that makes medical products and runs hospitals. Its product side, Fresenius Kabi, sells things like IV fluids, injectable medicines, clinical nutrition products, infusion pumps, and other supplies used in hospitals and clinics. Its hospital side treats patients through large hospital networks in Germany and Spain, where it provides inpatient care, surgeries, and related medical services.
The company makes money in two main ways. First, it sells healthcare products to hospitals, pharmacies, and other medical providers. Second, its hospital businesses are paid by insurers, public health systems, and patients for treatment and procedures. That mix gives Fresenius a role on both sides of the healthcare system: it supplies the tools doctors need and also delivers the care itself.
What makes Fresenius different is that it sits close to the core of everyday healthcare rather than selling optional consumer products. Demand for its services and supplies is tied to surgery, chronic illness treatment, and routine hospital care, which makes the business easy to understand: when hospitals need dependable medical consumables and when patients need care, Fresenius is often part of the chain.
Guidance Raised: Fresenius raised its full-year EBIT growth guidance to 4%–8%, up from 3%–7%, reflecting strong year-to-date performance and operational momentum.
EPS Growth: Core EPS grew by 14% in Q3, driven by strong operating results and a significant decrease in interest expenses.
Kabi Margin Strength: Kabi delivered an EBIT margin of 16.7% in Q3, with biopharma as a standout contributor and ongoing margin expansion.
Cash Flow & Deleveraging: Strong operating cash flow and continued deleveraging; leverage ratio now at 3x net debt to EBITDA, within the company’s target range.
Product Innovation: Multiple new product launches, especially in biosimilars and nutrition, are fueling growth and margin improvements.
Helios Stability: Helios maintained solid EBIT margins despite reimbursement changes and one-off items in Germany and Spain.
Investment & AI: The company plans to make further targeted investments, including in AI and digital initiatives, while balancing with deleveraging.
